Co-crystals
OwnerPeng LIinventor
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to co-crystals of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one, compositions comprising the same, as well as methods of making and using such co-crystals.
Claims44
A co-crystal comprising:
- A) (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one (Compound 1) in free, pharmaceutically acceptable salt or prodrug form, including its enantiomers, diastereoisomers and racemates;
- and
- B) a co-crystal former.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A process for the production of a co-crystal comprising (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one (Compound 1) in free, pharmaceutically acceptable salt or prodrug form, including its enantiomers, diastereoisomers and racemates;
- and a co-crystal former, the method comprising the steps of reacting Compound 1 with the co-crystal former and isolating the obtained co-crystal.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.